These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 2233610)
1. [Long-term therapy of tumor pain using morphine-retard tablets]. Sorge J; Lehmkuhl C; Lohse K; Herrmann H; Pichlmayr I Med Klin (Munich); 1990 Sep; 85(9):523-8. PubMed ID: 2233610 [TBL] [Abstract][Full Text] [Related]
2. [Effects of sustained release morphine hydrochloride tablets in management of cancer pain: a survey of 567 patients]. Yu SY; Qiu H; Ma ZS; Chen J; Zhang Y; Chen LZ; Wang DL; Ma ZY Zhonghua Yi Xue Za Zhi; 2004 Mar; 84(6):450-5. PubMed ID: 15061959 [TBL] [Abstract][Full Text] [Related]
3. [Retard morphine in the long-term therapy of severe tumor pain]. Zenz M; Strumpf M; Tryba M; Röhrs E; Steffmann B Dtsch Med Wochenschr; 1989 Jan; 114(2):43-7. PubMed ID: 2910700 [TBL] [Abstract][Full Text] [Related]
4. [Morphine tablets for chronic non-tumor-induced pain. Which factors modify the success or failure of a long-term therapy?]. Schulzeck S; Gleim M; Maier C Anaesthesist; 1993 Aug; 42(8):545-56. PubMed ID: 8368476 [TBL] [Abstract][Full Text] [Related]
5. Control of severe pain with sustained-release morphine tablets v. oral morphine solution. Arkinstall WW; Goughnour BR; White JA; Stewart JH CMAJ; 1989 Mar; 140(6):653-7, 661. PubMed ID: 2645988 [TBL] [Abstract][Full Text] [Related]
6. Comparison of TTS-fentanyl with sustained-release oral morphine in the treatment of patients not using opioids for mild-to-moderate pain. van Seventer R; Smit JM; Schipper RM; Wicks MA; Zuurmond WW Curr Med Res Opin; 2003; 19(6):457-69. PubMed ID: 14594516 [TBL] [Abstract][Full Text] [Related]
7. Principles of cancer pain management. Use of long-acting oral morphine. Brooks I; De Jager R; Blumenreich M; George E; Savarese JJ J Fam Pract; 1989 Mar; 28(3):275-80. PubMed ID: 2647896 [TBL] [Abstract][Full Text] [Related]
8. Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine. Wirz S; Wittmann M; Schenk M; Schroeck A; Schaefer N; Mueller M; Standop J; Kloecker N; Nadstawek J Eur J Pain; 2009 Aug; 13(7):737-43. PubMed ID: 18977159 [TBL] [Abstract][Full Text] [Related]
9. Guidelines for use of controlled-release oral morphine in cancer pain management. Correlation with clinical experience. Lapin J; Portenoy RK; Coyle N; Houde RW; Foley KM Cancer Nurs; 1989 Aug; 12(4):202-8. PubMed ID: 2766263 [TBL] [Abstract][Full Text] [Related]
10. Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain. Weinstein SM; Shi M; Buckley BJ; Kwarcinski MA Clin Ther; 2006 Jan; 28(1):86-98. PubMed ID: 16490582 [TBL] [Abstract][Full Text] [Related]
11. Experience with a controlled-release oral morphine for cancer pain management. Kim BS; Chung HC Postgrad Med J; 1991; 67 Suppl 2():S82-6. PubMed ID: 1758823 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain. Clark AJ; Ahmedzai SH; Allan LG; Camacho F; Horbay GL; Richarz U; Simpson K Curr Med Res Opin; 2004 Sep; 20(9):1419-28. PubMed ID: 15383190 [TBL] [Abstract][Full Text] [Related]
13. Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. Bruera E; Palmer JL; Bosnjak S; Rico MA; Moyano J; Sweeney C; Strasser F; Willey J; Bertolino M; Mathias C; Spruyt O; Fisch MJ J Clin Oncol; 2004 Jan; 22(1):185-92. PubMed ID: 14701781 [TBL] [Abstract][Full Text] [Related]
14. A clinical survey of controlled-release morphine sulphate for cancer pain relief in a Japanese hospice. Tsuneto S; Hayashi A; Miyazaki M; Kashiwagi T Postgrad Med J; 1991; 67 Suppl 2():S79-81. PubMed ID: 1758822 [TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind, multi-site, crossover, placebo-controlled equivalence study of morning versus evening once-daily sustained-release morphine sulfate in people with pain from advanced cancer. Currow DC; Plummer JL; Cooney NJ; Gorman D; Glare PA J Pain Symptom Manage; 2007 Jul; 34(1):17-23. PubMed ID: 17601560 [TBL] [Abstract][Full Text] [Related]
16. [Immediate-acting oral morphine sulfate in patients with cancer pain]. Montejo-Rosas G; Flores-Siordia R; Castañeda-de la Lanz C; Zavala-Sánchez A; Nápoles-Echauri A Gac Med Mex; 1998; 134(2):161-7. PubMed ID: 9618995 [TBL] [Abstract][Full Text] [Related]
17. Effervescent morphine results in faster relief of breakthrough pain in patients compared to immediate release morphine sulfate tablet. Freye E; Levy JV; Braun D Pain Pract; 2007 Dec; 7(4):324-31. PubMed ID: 17986159 [TBL] [Abstract][Full Text] [Related]
18. Postoperative intravenous morphine consumption, pain scores, and side effects with perioperative oral controlled-release oxycodone after lumbar discectomy. Blumenthal S; Min K; Marquardt M; Borgeat A Anesth Analg; 2007 Jul; 105(1):233-7. PubMed ID: 17578980 [TBL] [Abstract][Full Text] [Related]
19. [Comparison of TD-fentanyl with sustained-release morphine in the pain treatment of patients with lung cancer]. Oztürk T; Karadibak K; Catal D; Cakan A; Tugsavul F; Cirak K Agri; 2008 Jul; 20(3):20-5. PubMed ID: 19085178 [TBL] [Abstract][Full Text] [Related]
20. [Cancer pain therapy in children and adolescents using morphine]. Sittl R; Richter R Anaesthesist; 1991 Feb; 40(2):96-9. PubMed ID: 2048710 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]